BIOX: Revenue fell 18% amid restructuring, but cost cuts drove EBITDA improvement and margin targets
Fiscal 2026 saw an 18% revenue decline due to litigation and business restructuring, but cost reductions led to improved adjusted EBITDA and stabilization in core segments. The company targets 40% gross margins and further SG&A reductions, with ongoing focus on liquidity and legal matters.Based on…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.